María Antonia Gomis-Font
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Antonia Gomis-Font has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Oliver
CIBER de Enfermedades Infecciosas (CIBERInfec), Instituto de Salud Carlos III
7 shared publications - Alejandro Beceiro
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña
4 shared publications - Germán Bou
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña
4 shared publications - Jorge Arca-Suárez
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña
4 shared publications - Lucía González-Pinto
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña
4 shared publications - Salud Rodríguez-Pallares
Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0180525
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa
We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The bla OXA-1054 gene was cloned in parallel with bla OXA-48 and bla OXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The bla OXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa , including carbapenems and β-lactam/β-lactamase inhibitor combinations.
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0180525
Open AccessGenetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa
We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The bla OXA-1054 gene was cloned in parallel with bla OXA-48 and bla OXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The bla OXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa , including carbapenems and β-lactam/β-lactamase inhibitor combinations.
- Open Access
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0116325
First nationwide survey on Pseudomonas aeruginosa in Bolivia: susceptibility profiles, resistome, and genomic epidemiology
Information on the molecular epidemiology of Pseudomonas aeruginosa and antimicrobial resistance mechanisms is still limited in some South American countries. This study aims to decipher the population structure of 111 extensive drug-resistant P. aeruginosa isolates from a national study conducted in Bolivia during 2023–2024. The antibiotic susceptibility profiles were determined for 15 antipseudomonal agents. All isolates were subjected to whole-genome sequencing (WGS), and, through bioinformatics analysis, sequence types (ST), clonal relatedness, and acquired mutation-driven and transferable resistance mechanisms were elucidated. The most active antipseudomonal agents were colistin (98.2% intermediate, MIC 50/90 =1/2 mg/L) and cefiderocol (92.7% susceptible, MIC 50/90 =0.25/4 mg/L) according to the Clinical and Laboratory Standards Institute (CLSI). High resistance rates to ceftazidime/avibactam (79.3%), ceftolozane/tazobactam (82.9%), and imipenem/relebactam (71.2%) were documented. Carbapenemases were found in 60.3%, particularly including metallo-β-lactamases (MBL), such as SPM-1 (35%), VIM-2 (9%), the co-production of NDM-1 and DIM-1 (4%), or the new IMP variant IMP-111. Extended-spectrum β-lactamases (ESBLs) were detected in 12% of the isolates, including OXA-17 (7%), PER-1 (3%), and some GES variants. The most commonly detected clone was ST277 (35%) associated with SPM-1, followed by the ST309 (25%) producer of OXA-2 and various GES, and ST235 (20%) related with OXA-17 and new IMP-111. These clones harbored other acquired resistance genes, including emerging 16S rRNA methyltransferases, RmtD and RmtG. The high resistance rates for novel beta-lactams linked to an alarming spread of high-risk clones ST277 and ST235 and the very high prevalence of MBLs and ESBLs raise significant concern. This underscores the urgent need for establishing epidemiological surveillance and infection control strategies.
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0116325
Open AccessFirst nationwide survey on Pseudomonas aeruginosa in Bolivia: susceptibility profiles, resistome, and genomic epidemiology
Information on the molecular epidemiology of Pseudomonas aeruginosa and antimicrobial resistance mechanisms is still limited in some South American countries. This study aims to decipher the population structure of 111 extensive drug-resistant P. aeruginosa isolates from a national study conducted in Bolivia during 2023–2024. The antibiotic susceptibility profiles were determined for 15 antipseudomonal agents. All isolates were subjected to whole-genome sequencing (WGS), and, through bioinformatics analysis, sequence types (ST), clonal relatedness, and acquired mutation-driven and transferable resistance mechanisms were elucidated. The most active antipseudomonal agents were colistin (98.2% intermediate, MIC 50/90 =1/2 mg/L) and cefiderocol (92.7% susceptible, MIC 50/90 =0.25/4 mg/L) according to the Clinical and Laboratory Standards Institute (CLSI). High resistance rates to ceftazidime/avibactam (79.3%), ceftolozane/tazobactam (82.9%), and imipenem/relebactam (71.2%) were documented. Carbapenemases were found in 60.3%, particularly including metallo-β-lactamases (MBL), such as SPM-1 (35%), VIM-2 (9%), the co-production of NDM-1 and DIM-1 (4%), or the new IMP variant IMP-111. Extended-spectrum β-lactamases (ESBLs) were detected in 12% of the isolates, including OXA-17 (7%), PER-1 (3%), and some GES variants. The most commonly detected clone was ST277 (35%) associated with SPM-1, followed by the ST309 (25%) producer of OXA-2 and various GES, and ST235 (20%) related with OXA-17 and new IMP-111. These clones harbored other acquired resistance genes, including emerging 16S rRNA methyltransferases, RmtD and RmtG. The high resistance rates for novel beta-lactams linked to an alarming spread of high-risk clones ST277 and ST235 and the very high prevalence of MBLs and ESBLs raise significant concern. This underscores the urgent need for establishing epidemiological surveillance and infection control strategies.
- Open Access
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0104825
Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases. We evaluated the contribution of Pseudomonas aeruginosa resistance mechanisms to cefiderocol/xeruborbactam susceptibility. A panel of 61 P . aeruginosa PAO1 derivatives was tested, including 20 knockout mutants representing key chromosomal resistance mechanisms (e.g., ampC overexpression, efflux upregulation, porin loss, iron uptake deficiency) and 41 transformants producing major circulating β-lactamases. Xeruborbactam was assessed in combination with cefiderocol and cefepime at 4 and 8 mg/L and compared with taniborbactam. Additionally, 99 cefiderocol-resistant clinical P. aeruginosa isolates were evaluated. Cefiderocol/xeruborbactam retained activity against most P. aeruginosa mutants with chromosomally encoded resistance mechanisms. However, the P. aeruginosa piuC- defective mutant yielded increased cefiderocol minimum inhibitory concentrations (MIC = 2 mg/L), which could not be restored by xeruborbactam. Xeruborbactam significantly increased the activity of cefiderocol against the majority of P. aeruginosa PAO1 transformants, including those producing PER-1, SHV-12, KPC Ω-loop mutants, or NDM variants. Cefiderocol/xeruborbactam was active against IMP-type MBLs (which only weakly hydrolyze cefiderocol), including xeruborbactam-resistant enzymes. Relative to taniborbactam, xeruborbactam-based combinations showed similar activity against P. aeruginosa PAO1 transformants, but with slightly higher MIC values when tested against metallo-β-lactamase producers. This MIC increase in xeruborbactam-based combinations was partly because of the constitutive MexAB-OprM efflux in the P. aeruginosa background, as confirmed with P. aeruginosa PAO1 efflux mutants. Importantly, xeruborbactam restored susceptibility in 78% of 99 cefiderocol-resistant P. aeruginosa strains, reducing the MIC 90 from 64 to 4 mg/L. Cefiderocol/xeruborbactam shows promising activity against P. aeruginosa .
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0104825
Open AccessContribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases. We evaluated the contribution of Pseudomonas aeruginosa resistance mechanisms to cefiderocol/xeruborbactam susceptibility. A panel of 61 P . aeruginosa PAO1 derivatives was tested, including 20 knockout mutants representing key chromosomal resistance mechanisms (e.g., ampC overexpression, efflux upregulation, porin loss, iron uptake deficiency) and 41 transformants producing major circulating β-lactamases. Xeruborbactam was assessed in combination with cefiderocol and cefepime at 4 and 8 mg/L and compared with taniborbactam. Additionally, 99 cefiderocol-resistant clinical P. aeruginosa isolates were evaluated. Cefiderocol/xeruborbactam retained activity against most P. aeruginosa mutants with chromosomally encoded resistance mechanisms. However, the P. aeruginosa piuC- defective mutant yielded increased cefiderocol minimum inhibitory concentrations (MIC = 2 mg/L), which could not be restored by xeruborbactam. Xeruborbactam significantly increased the activity of cefiderocol against the majority of P. aeruginosa PAO1 transformants, including those producing PER-1, SHV-12, KPC Ω-loop mutants, or NDM variants. Cefiderocol/xeruborbactam was active against IMP-type MBLs (which only weakly hydrolyze cefiderocol), including xeruborbactam-resistant enzymes. Relative to taniborbactam, xeruborbactam-based combinations showed similar activity against P. aeruginosa PAO1 transformants, but with slightly higher MIC values when tested against metallo-β-lactamase producers. This MIC increase in xeruborbactam-based combinations was partly because of the constitutive MexAB-OprM efflux in the P. aeruginosa background, as confirmed with P. aeruginosa PAO1 efflux mutants. Importantly, xeruborbactam restored susceptibility in 78% of 99 cefiderocol-resistant P. aeruginosa strains, reducing the MIC 90 from 64 to 4 mg/L. Cefiderocol/xeruborbactam shows promising activity against P. aeruginosa .
- Open Access
- 27 May 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (7) , e0029225
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa
A wide variety of clinically observed amino acid alterations in the Pseudomonas aeruginosa chromosomal β-lactamase AmpC ( Pseudomonas -derived cephalosporinase [PDC]) are associated with increased resistance to cefepime, ceftolozane/tazobactam, or ceftazidime/avibactam, but their impact on cefiderocol resistance is unclear. We took advantage of a previously engineered collection of wild-type (PAO1) and iron uptake-deficient (PAO Δ piuC ) P. aeruginosa isolates producing 19 distinct PDC variants with substitutions in key catalytic regions. While most variants had moderate effects on cefiderocol minimum inhibitory concentrations compared to PDC-1, the E219K (Ω-loop) and L293P (helix H10) variants significantly affected cefiderocol activity. Kinetic studies revealed that both mutations improve cefiderocol hydrolysis through different enzymatic mechanisms compared to PDC-1 ( K m = 85.29 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00004 µM −1 s −1 ), leading to enhanced turnover in PDC E219K ( K m = 465.64 µM, k cat = 0.45 s −1 , and k cat / K m = 0.00096 µM −1 s −1 ) and improved affinity in PDC L293P ( K m = 2.69 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00135 µM −1 s −1 ). These mechanisms are also involved in resistance to ceftolozane and cefepime, identified as the preferred substrates for the E219K and L293P variants, respectively. Molecular dynamics (MD) simulation studies revealed that (i) rigidification of the Ω-loop in PDC E219K promotes optimal accommodation of the R 1 group of cefiderocol, enhancing nucleophilic attack by the catalytic serine; (ii) the less folded conformation of helix H10 in PDC L293P improves cefiderocol accommodation in the active site by establishing stronger hydrogen-bonding interactions with the R 2 group. Our findings demonstrate that the PDC β-lactamase may take advantage of the structural similarities between cefiderocol and other cephalosporins and accelerate hydrolysis by accommodating the E219K or L293P amino acid replacements.
- 27 May 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (7) , e0029225
Open AccessFunctional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa
A wide variety of clinically observed amino acid alterations in the Pseudomonas aeruginosa chromosomal β-lactamase AmpC ( Pseudomonas -derived cephalosporinase [PDC]) are associated with increased resistance to cefepime, ceftolozane/tazobactam, or ceftazidime/avibactam, but their impact on cefiderocol resistance is unclear. We took advantage of a previously engineered collection of wild-type (PAO1) and iron uptake-deficient (PAO Δ piuC ) P. aeruginosa isolates producing 19 distinct PDC variants with substitutions in key catalytic regions. While most variants had moderate effects on cefiderocol minimum inhibitory concentrations compared to PDC-1, the E219K (Ω-loop) and L293P (helix H10) variants significantly affected cefiderocol activity. Kinetic studies revealed that both mutations improve cefiderocol hydrolysis through different enzymatic mechanisms compared to PDC-1 ( K m = 85.29 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00004 µM −1 s −1 ), leading to enhanced turnover in PDC E219K ( K m = 465.64 µM, k cat = 0.45 s −1 , and k cat / K m = 0.00096 µM −1 s −1 ) and improved affinity in PDC L293P ( K m = 2.69 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00135 µM −1 s −1 ). These mechanisms are also involved in resistance to ceftolozane and cefepime, identified as the preferred substrates for the E219K and L293P variants, respectively. Molecular dynamics (MD) simulation studies revealed that (i) rigidification of the Ω-loop in PDC E219K promotes optimal accommodation of the R 1 group of cefiderocol, enhancing nucleophilic attack by the catalytic serine; (ii) the less folded conformation of helix H10 in PDC L293P improves cefiderocol accommodation in the active site by establishing stronger hydrogen-bonding interactions with the R 2 group. Our findings demonstrate that the PDC β-lactamase may take advantage of the structural similarities between cefiderocol and other cephalosporins and accelerate hydrolysis by accommodating the E219K or L293P amino acid replacements.
- Open Access
- 11 February 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 174
Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147
- 11 February 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 174
Open AccessCorrection: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii. Antibiotics 2024, 13, 1147
- Open Access
- 1 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (12) , 1147
Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii
Background/Objectives: Acinetobacter baumannii is a globally emerging pathogen with widespread antimicrobial resistance driven by multiple mechanisms, such as altered expression of efflux pumps like AdeABC, placing it as a priority for research. Driven by the lack of new treatments, alternative approaches are being explored to combat its infections, among which efficacy-enhancing adjuvants can be found. This study presents and characterizes MV6, a synthetic cyclic peptide that boosts aminoglycoside efficacy. Methods: MV6’s activity was assessed through antimicrobial susceptibility testing in combination with different antibiotic classes against A. baumannii strains characterized by PCR and RT-qPCR. PAβN served as a reference efflux pump inhibitor. Synergy was evaluated using checkerboard assays, and spontaneous mutants were generated with netilmicin with/without MV6 (100 mg/L). Whole-genome sequencing and variant calling analysis were then performed. Results: MV6 presented low antimicrobial activity in A. baumannii with MICs higher than 2048 mg/L. MV6 showed a better boosting effect for aminoglycosides, especially netilmicin, exceeding that of PAβN. Checkerboard assays confirmed a strong synergy between netilmicin and MV6, and a significant correlation was found between netilmicin MIC and adeB overexpression, which was mitigated by the presence of MV6. MV6 reduced, by 16-fold, the mutant prevention concentration of netilmicin. Mutations in a TetR-family regulator and ABC-binding proteins were found in both groups, suggesting a direct or indirect implication of these proteins in the resistance acquisition process. Conclusions: MV6 lacks intrinsic antimicrobial activity, minimizing selective pressure, yet enhances netilmicin’s effectiveness except for strain 210, which lacks the AdeABC efflux pump. Resistant mutants indicate specific aminoglycoside resistance mechanisms involving efflux pump mutations, suggesting synergistic interactions. Further research, including transcriptomic analysis, is essential to elucidate MV6’s role in enhancing netilmicin efficacy and its resistance mechanisms.
- 1 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (12) , 1147
Open AccessCyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against Acinetobacter baumannii
Background/Objectives: Acinetobacter baumannii is a globally emerging pathogen with widespread antimicrobial resistance driven by multiple mechanisms, such as altered expression of efflux pumps like AdeABC, placing it as a priority for research. Driven by the lack of new treatments, alternative approaches are being explored to combat its infections, among which efficacy-enhancing adjuvants can be found. This study presents and characterizes MV6, a synthetic cyclic peptide that boosts aminoglycoside efficacy. Methods: MV6’s activity was assessed through antimicrobial susceptibility testing in combination with different antibiotic classes against A. baumannii strains characterized by PCR and RT-qPCR. PAβN served as a reference efflux pump inhibitor. Synergy was evaluated using checkerboard assays, and spontaneous mutants were generated with netilmicin with/without MV6 (100 mg/L). Whole-genome sequencing and variant calling analysis were then performed. Results: MV6 presented low antimicrobial activity in A. baumannii with MICs higher than 2048 mg/L. MV6 showed a better boosting effect for aminoglycosides, especially netilmicin, exceeding that of PAβN. Checkerboard assays confirmed a strong synergy between netilmicin and MV6, and a significant correlation was found between netilmicin MIC and adeB overexpression, which was mitigated by the presence of MV6. MV6 reduced, by 16-fold, the mutant prevention concentration of netilmicin. Mutations in a TetR-family regulator and ABC-binding proteins were found in both groups, suggesting a direct or indirect implication of these proteins in the resistance acquisition process. Conclusions: MV6 lacks intrinsic antimicrobial activity, minimizing selective pressure, yet enhances netilmicin’s effectiveness except for strain 210, which lacks the AdeABC efflux pump. Resistant mutants indicate specific aminoglycoside resistance mechanisms involving efflux pump mutations, suggesting synergistic interactions. Further research, including transcriptomic analysis, is essential to elucidate MV6’s role in enhancing netilmicin efficacy and its resistance mechanisms.
- 17 September 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (11) , 3023-3028
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa
We aimed to analyse the interplay between impaired iron uptake and β-lactamases on cefiderocol resistance in Pseudomonas aeruginosa. Thirty-one transferable β-lactamases and 16 intrinsic P. aeruginosa AmpC (PDC) variants were cloned and expressed in wild-type (PAO1) and iron uptake-deficient (PAO ΔpiuC) P. aeruginosa backgrounds. MICs of cefiderocol and antipseudomonal β-lactams were determined by reference broth microdilution. Relative to PAO1, deletion of piuC caused a specific 16-fold decrease in cefiderocol activity but negligible effects on the activity of other β-lactams. Among transferable β-lactamases, SHV-12, KPC Ω-loop mutants, NDMs and OXA-15 showed cefiderocol MIC values above the clinical breakpoint (2 mg/L) when expressed in PAO1. When expressed in PAO ΔpiuC, these and the transformants harbouring PER-1, VEB-1, KPC-2, KPC-3, VIM-1, CMY-2, OXA-2 and OXA-14 showed increased MIC values from 16 to >256 mg/L. The PDC variants carrying the Ω-loop changes ΔP215-G222 (PDC-577), E219K (PDC-221 and PDC-558) and the H10 helix change L293P (PDC-219) had the greatest impact on cefiderocol resistance, with MICs of 2–4 mg/L in PAO1 and of up to 32–64 mg/L in PAO ΔpiuC. Widespread enzymes such as GES, CTX-M-9, CTX-M-15, VIM-2-like enzymes, IMPs, DHA-1, FOX-4, OXA-10, OXA-48 and the other PDC variants tested had weaker effects on cefiderocol resistance. We add evidence about the effect of the interplay between iron uptake and β-lactamases on the acquisition of cefiderocol resistance in P. aeruginosa. These findings may help to anticipate the emergence of resistance and optimize the use of cefiderocol against P. aeruginosa infections.
- 17 September 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (11) , 3023-3028
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa
We aimed to analyse the interplay between impaired iron uptake and β-lactamases on cefiderocol resistance in Pseudomonas aeruginosa. Thirty-one transferable β-lactamases and 16 intrinsic P. aeruginosa AmpC (PDC) variants were cloned and expressed in wild-type (PAO1) and iron uptake-deficient (PAO ΔpiuC) P. aeruginosa backgrounds. MICs of cefiderocol and antipseudomonal β-lactams were determined by reference broth microdilution. Relative to PAO1, deletion of piuC caused a specific 16-fold decrease in cefiderocol activity but negligible effects on the activity of other β-lactams. Among transferable β-lactamases, SHV-12, KPC Ω-loop mutants, NDMs and OXA-15 showed cefiderocol MIC values above the clinical breakpoint (2 mg/L) when expressed in PAO1. When expressed in PAO ΔpiuC, these and the transformants harbouring PER-1, VEB-1, KPC-2, KPC-3, VIM-1, CMY-2, OXA-2 and OXA-14 showed increased MIC values from 16 to >256 mg/L. The PDC variants carrying the Ω-loop changes ΔP215-G222 (PDC-577), E219K (PDC-221 and PDC-558) and the H10 helix change L293P (PDC-219) had the greatest impact on cefiderocol resistance, with MICs of 2–4 mg/L in PAO1 and of up to 32–64 mg/L in PAO ΔpiuC. Widespread enzymes such as GES, CTX-M-9, CTX-M-15, VIM-2-like enzymes, IMPs, DHA-1, FOX-4, OXA-10, OXA-48 and the other PDC variants tested had weaker effects on cefiderocol resistance. We add evidence about the effect of the interplay between iron uptake and β-lactamases on the acquisition of cefiderocol resistance in P. aeruginosa. These findings may help to anticipate the emergence of resistance and optimize the use of cefiderocol against P. aeruginosa infections.